CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK) has presented early-stage clinical trial results for CT0596, its allogeneic BCMA-targeted CAR-T cell product candidate, at the 67th American Society of Hematology (ASH) Annual Meeting, highlighting promising initial responses in patients with relapsed or refractory multiple myeloma (R/R MM).
The results, featured in poster presentation number 2296, mark the first human trial data shared for CT0596 and suggest that the therapy may offer a new treatment option for heavily pretreated patients, particularly those with limited alternatives following multiple prior lines of therapy.
The clinical study, identified as NCT06718270, included a dose-escalation phase involving eight patients with R/R MM. Patients had received a median of 4.5 prior lines of therapy, with the range spanning from three to nine. Notably, patient selection was not limited by NKG2A expression levels, indicating a broader potential patient population for the therapy under investigation.
What patient responses and safety outcomes were observed in the CT0596 trial?
As of the August 31, 2025 data cutoff, all eight participants who had received the CT0596 infusion were evaluable for efficacy, with a median follow-up duration of just over four months. Among these, six patients achieved partial response (PR) or better, including three patients who reached either complete response (CR) or stringent complete response (sCR). These deeper responses were only observed in patients who underwent full-dose lymphodepletion, suggesting a correlation between the conditioning regimen and treatment outcomes.
One patient, identified as Patient 01, maintained both sCR and minimal residual disease (MRD) negativity for eight months post-infusion. Additionally, Patient 04 achieved a partial response that included the resolution of extramedullary disease following a second infusion.
Six patients received full-dose lymphodepletion using a combination of fludarabine (30 mg/m²/day) and cyclophosphamide (500 mg/m²/day) for three consecutive days. The remaining two participants underwent reduced-dose lymphodepletion. CAR-T cell expansion was observed in all patients, and six of those treated with the full-dose regimen achieved MRD negativity at Week 4, reinforcing the biological activity of the therapy.
Dosing levels for CT0596 ranged from 1.5×10⁸ to 4.5×10⁸ CAR-T cells, with one patient receiving two separate infusions. Among those who received the highest dose level, one achieved sCR, while the other demonstrated a deepening response to very good partial response (VGPR), further supporting a potential dose–response relationship.
What are the next steps for CT0596 after dose-escalation phase completion?
CT0596 continues to be evaluated in the dose-exploration phase, where higher cell doses are being tested to determine the recommended Phase 1b dose. The lymphodepletion regimen has now been finalized based on the observed efficacy and safety signals.
Looking ahead, CARsgen Therapeutics plans to initiate a Phase 1b registrational trial for CT0596 in 2026. This expansion study will likely assess additional dosing cohorts and further evaluate the durability of responses observed in the initial cohort.
The cell therapy product is being developed using CARsgen’s proprietary THANK-u Plus platform, which supports the production of allogeneic CAR-T cells that do not require patient-specific T-cell harvesting. This could significantly reduce manufacturing timelines and broaden clinical accessibility, especially for patients with rapidly progressing disease.
How did CT0596 perform on safety metrics including CRS and neurotoxicity?
The preliminary safety profile of CT0596 appeared manageable, with no serious adverse events reported through the data cutoff. Four of the eight patients experienced Grade 1 cytokine release syndrome (CRS), a known complication of CAR-T therapy, but no Grade 2 or higher CRS events occurred.
Importantly, no cases of immune effector cell-associated neurotoxicity syndrome (ICANS) or graft-versus-host disease (GVHD) were reported. There were also no dose-limiting toxicities, treatment discontinuations, or deaths observed in the early cohort, adding to the early confidence in the product’s safety signal as it moves into further clinical development.
What strategic pipeline goals is CARsgen pursuing with CT0596?
Beyond R/R multiple myeloma, CT0596 is also being evaluated in investigator-initiated studies for plasma cell leukemia (PCL) and other plasma cell malignancies. The cell therapy may also hold future promise in autoimmune conditions mediated by aberrant plasma cell populations, based on the mechanism of BCMA targeting and initial tolerability.
CARsgen anticipates submitting an Investigational New Drug (IND) application in the second half of 2025 to support formal expansion of clinical trials into broader patient populations.
With CT0596 representing the company’s lead allogeneic candidate, the strategy signals a growing focus on off-the-shelf cell therapies that overcome the cost and logistical barriers associated with autologous CAR-T platforms.
How does CT0596 fit within CARsgen’s broader innovation roadmap?
CARsgen Therapeutics has built an integrated pipeline of CAR-T candidates spanning both hematologic malignancies and solid tumors. The Chinese biopharmaceutical company is one of a few emerging players developing in-house technologies across the full R&D and manufacturing spectrum, including target discovery, clinical validation, and commercial-scale production.
The THANK-u Plus platform powering CT0596 is part of the company’s effort to optimize T-cell fitness, persistence, and tumor targeting while reducing immune-related toxicity and treatment costs.
Other proprietary assets include CARsgen’s anti-CLDN18.2 CAR-T candidate for gastric and pancreatic cancers, positioning the firm among a new wave of global players developing solid tumor-focused immunotherapies with next-generation cell engineering approaches.
What does the clinical community think about early CT0596 results?
Analysts and immunotherapy experts tracking the field of next-generation CAR-T development view CT0596’s early data as encouraging but preliminary. While the small cohort size limits statistical confidence, the multiple deep responses and MRD negativity at four weeks suggest a meaningful level of anti-myeloma activity.
The absence of severe CRS or neurotoxicity also stands out, particularly as allogeneic cell therapies can sometimes trigger greater immunologic complications compared to autologous approaches. If larger trials confirm these safety trends, CT0596 could represent a scalable and more readily available alternative to existing BCMA CAR-T therapies like idecabtagene vicleucel (Abecma) and ciltacabtagene autoleucel (Carvykti).
Going forward, the upcoming Phase 1b trial in 2026 will be closely watched for updated efficacy data, duration of response, and clinical benefit across more diverse patient groups.
What are the key takeaways from CARsgen’s CT0596 ASH 2025 presentation?
- CARsgen presented initial human trial data for CT0596, an allogeneic BCMA-targeted CAR-T therapy, at ASH 2025.
- The trial involved eight heavily pretreated multiple myeloma patients, with six achieving partial response or better.
- Deep responses including stringent complete response and MRD negativity were observed in patients receiving full-dose lymphodepletion.
- Safety profile was manageable with only mild CRS reported; no neurotoxicity or GVHD observed.
- A Phase 1b registrational trial is planned for 2026, with CT0596 also being explored in plasma cell leukemia and autoimmune disease settings.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
